Emma L. Turner
A5061314905- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Long-Term Effects of COVID-19
- Bladder and Urothelial Cancer Treatments
- Ethics in Clinical Research
- Statistical Methods in Clinical Trials
- COVID-19 and Mental Health
- COVID-19 Clinical Research Studies
- Intensive Care Unit Cognitive Disorders
- Health disparities and outcomes
- Genomics and Chromatin Dynamics
- Cancer Risks and Factors
- Microtubule and mitosis dynamics
- Healthcare Policy and Management
- Statistical Methods and Inference
- Patient-Provider Communication in Healthcare
- Epigenetics and DNA Methylation
- Delphi Technique in Research
- Psychology of Moral and Emotional Judgment
- Vaccine Coverage and Hesitancy
- Cancer survivorship and care
- Genetic Associations and Epidemiology
University of Bristol
2016-2025
Bristol Regional Medical Center
2025
BenevolentAI (United Kingdom)
2025
George Washington University
2025
Imperial College London
2022-2024
Birmingham Women’s and Children’s NHS Foundation Trust
2024
Tameside and Glossop Integrated Care NHS Foundation Trust
2024
Collaborative Group (United States)
2023
NIHR Leicester Biomedical Research Centre
2021-2023
University of Leicester
2021-2023
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radiotherapy with hormones outcomes.
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
Importance Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective To evaluate the effect of a single prostate-specific antigen (PSA) intervention standardized diagnostic pathway on prostate cancer–specific mortality. Design, Setting, Participants The Cluster Randomized Trial PSA Testing for Cancer (CAP) included 419 582 men aged 50 to 69 years was conducted at 573...
Prostate cancer is a major public health problem with considerable uncertainties about the effectiveness of population screening and treatment options. We report study design, participant sociodemographic clinical characteristics, initial results testing diagnostic phase for Treatment (ProtecT) trial, which aims to investigate treatments localised prostate cancer.
BackgroundLong-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer.MethodsPatient-reported of 1643 randomly assigned participants in the ProtecT (Prostate Testing Cancer and Treatment) trial were evaluated assess functional quality-of-life impacts prostatectomy, radiotherapy with neoadjuvant androgen deprivation, active monitoring. This article focuses on from 7 12 years using mixed effects linear logistic models.ResultsResponse rates...
Importance The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary outcome), but the long-term effects remain unclear. Objective To evaluate single invitation cancer–specific 15-year compared with screening. Design, Setting, and Participants This secondary analysis CAP randomized clinical trial included men aged 50 to 69 years identified 573 primary...
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. To determine report outcomes according treatment received in randomised choice cohorts. This study focuses on secondary care. Men clinically at one nine UK centres were invited participate the comparing AM, Two cohorts included 1643 who agreed be randomised; 997 declined randomisation chose...
To investigate the functional and quality of life (QoL) outcomes treatments for localised prostate cancer inform treatment decision-making.Men aged 50-69 years diagnosed with by prostate-specific antigen testing biopsies at nine UK centres in Prostate Testing Cancer Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) concurrent...
Objective To test the hypothesis that baseline clinico‐pathological features of men with localized prostate cancer (PCa) included in ProtecT (Prostate Testing for Cancer and Treatment) trial who progressed ( n = 198) at a 10‐year median follow‐up were different from those stable disease 1409). Patients Methods We stratified study participants according to risk progression using clinical stage, pathological grade PSA level, Cox proportional hazard models. Results The findings showed 34% 505)...
OBJECTIVE • To estimate rates of prostate-specific antigen (PSA) testing in UK general practices by age, deprivation index and geographical location. SUBJECTS AND METHODS Practice-based, retrospective data on PSA patterns 2007 were collected from a random sample 87 using EMIS LV computer systems within the passively observed non-intervention arm cluster-randomized controlled trial. Information for total 126 716 men aged 45-89 years with no recorded diagnosis prostate cancer prior to 1...
Abstract Observational studies suggest that diabetes is associated with a decreased risk of prostate cancer, but few are population based or have investigated associations cancer stage duration diabetes. We report case–control study nested within the population‐based Prostate testing for and Treatment (ProtecT) ISRCTN20141297. Men aged 50–69 years around 9 UK cities were invited prostate‐specific antigen (PSA) test between June 2002 November 2006. Amongst 55,215 PSA‐tested men, 1,966 had...
Background Prostate cancer is the most common among men in UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well undertreatment of disease. Evidence treatment effectiveness has lacked because paucity randomised controlled trials comparing conventional treatments. Objectives To evaluate treatments for localised prostate (active monitoring, radical prostatectomy and radiotherapy) aged 50–69 years. Design A prospective, multicentre...
Associations have been found between COVID-19 and subsequent mental illness in both hospital- population-based studies. However, evidence regarding which illnesses are associated with by vaccination status these populations is limited.
Accurate cause of death assignment is crucial for prostate cancer epidemiology and trials reporting cancer-specific mortality outcomes. We compared certificate information with independent evaluation by an expert committee within a trial (2002–2015). Of 1236 deaths assessed, attributed 523 (42%) to cancer, agreeing in 1134 cases (92%, 95% CI: 90%, 93%). The sensitivity certificates identifying as classified the was 91% (95% 89%, 94%); specificity 92% 94%). Sensitivity were lower where...
A polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and improved screening accuracy. Here, we assess potential impact PHS-informed screening.
Objectives Cross-sectional studies suggest that around 6% of men undergo prostate-specific antigen (PSA) testing each year in UK general practice (GP). This longitudinal study aims to determine the cumulative pattern over a 10-year period and whether this can be considered equivalent screening for prostate cancer (PCa). Setting, participants outcome measures Patient-level data on PSA tests, biopsies PCa diagnoses were obtained from Clinical Practice Research Datalink (CPRD) years 2002 2011....
To address the concern that polygenic hazard scores for prostate cancer (PCa) might not distinguish between indolent and aggressive disease, we performed case-only analyses using a 601-variant score (PHS601). We hypothesized among men who eventually developed PCa, those with higher PHS were more likely to develop disease. analyzed genetic phenotypic data from diverse, national cohort of diagnosed PCa (Million Veteran Program, n = 69,901, 6413 metastatic). used Cox proportional hazards models...